China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of all subjects and their clinical observation, alongside the clinical study summary report of a Phase I clinical study for its Category 1 GST-HG171. The results showed that GST-HG171 had good safety, tolerability, and pharmacokinetics, which achieved the intended purpose of the test and provides an essential basis for the upcoming Phase II/III clinical study.
GST-HG171: Mechanism and Efficacy
GST-HG171 is a 3CL protease (3CLpro) inhibitor described as having broad-spectrum anti-COVID-19 activities, with high-efficiency virus inhibitory activities against the original SARS-CoV-2 virus and Omicron BA.4 and BA.5 variants, as well as beta and delta variants. The drug candidate showed excellent antiviral efficacy on the COVID-19 animal model, showed high efficiency in reducing the lung viral load activity on the K18-hACE2 COVID-19 mouse model, and showed good safety in the GLP toxicological experiment in rats and dogs.-Fineline Info & Tech
